SELLAS Life Sciences Reports Strong Cash Position and Imminent Phase 3 Data Readout

summarizeSummary

SELLAS Life Sciences reported a robust cash position of $114.7 million (pro forma) and confirmed its Phase 3 GPS trial is nearing final data analysis, alongside continued progress for its SLS009 candidate.

check_boxKey Events

• Strengthened Cash Position

  The company reported $107.1 million in cash and cash equivalents as of March 31, 2026. This was significantly boosted by $44.1 million from warrant exercises during Q1 2026, with an additional $7.5 million received from warrant exercises subsequent to the quarter, bringing the pro forma cash balance to $114.7 million.

• Extended Cash Runway

  Management explicitly stated that the current cash and cash equivalents, including subsequent warrant proceeds, are sufficient to fund planned operations for at least the next twelve months, removing immediate going concern doubts.

• GPS Phase 3 Trial Nearing Final Analysis

  The Phase 3 REGAL study for GPS in AML has reached 78 out of 80 required events (deaths) as of May 11, 2026, indicating that the final data analysis is imminent. The interim analysis in January 2025 recommended continuing the study without modifications.

• SLS009 Pipeline Advancement

  The Phase 2 trial for SLS009 in r/r AML met all primary endpoints in July 2025, leading to FDA guidance to advance into a first-line therapy study, which began enrollment in Q1 2026. A new collaboration with IMPACT-AML will expand European patient access.

auto_awesomeAnalysis

SELLAS Life Sciences Group, Inc. reported a significantly strengthened cash position, with $107.1 million in cash and equivalents as of March 31, 2026, further bolstered by an additional $7.5 million from warrant exercises subsequent to the quarter. This substantial capital infusion, totaling $51.6 million from warrant exercises in and after Q1, extends the company's operational runway beyond 12 months and addresses prior liquidity concerns. The company also provided a critical update on its lead product candidate, GPS, with the Phase 3 REGAL study reaching 78 out of 80 required events, signaling an imminent final data analysis. Positive progress was also noted for SLS009, advancing to a first-line AML study and securing a European collaboration.